Innate Therapeutics

This technology can be used to induce the human immune system to fight certain cancers and infections, or turn off certain immune mechanisms which lead to autoimmune diseases such as Multiple Sclerosis. The same technology can also be used in the design of better vaccines to potentially treat or prevent diseases such as influenza, cancer, malaria, or tuberculosis.

The microparticle, which is currently produced under a GMP license from New Zealand's therapeutics regulator Medsafe, is the core of Innate Therapeutics's technology. The microparticle provides a unique delivery system for a suite of known and novel immune system triggers or modulators. By attaching selected modulators to the microparticle, these triggers can be delivered reliably to specific cells of the immune system.

The first drug candidate developed using this technology (MIS416), has demonstrated safety and efficacy in a number of different disease or injury models. Multiple Sclerosis has been selected as the disease target for a human Phase 2 programme which commenced in New Zealand during September 2010.

Website: http://www.innatetherapeutics.com/

The company profiled is one of the investment opportunities currently available in New Zealand. Please note that these opportunities are not endorsed or recommended by New Zealand Trade and Enterprise (NZTE) and may be updated from time to time. Investors are advised to contact our New Zealand-based Investment Specialist to discuss further and to conduct their own due diligence and independent advice on the relevant investment, before committing to any investment.